Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Volume Increase – Here’s What Happened

by · The Cerbat Gem

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 162,046 shares changed hands during trading, an increase of 225% from the previous session’s volume of 49,907 shares.The stock last traded at $14.03 and had previously closed at $13.63.

Analyst Ratings Changes

FSNUY has been the topic of a number of analyst reports. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Monday, October 27th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Check Out Our Latest Report on FSNUY

Fresenius SE & Co. Stock Up 3.4%

The company has a current ratio of 1.26, a quick ratio of 0.99 and a debt-to-equity ratio of 0.49. The firm’s fifty day moving average price is $14.76 and its 200-day moving average price is $13.56. The company has a market cap of $31.48 billion, a price-to-earnings ratio of 25.62 and a beta of 0.77.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.02. Fresenius SE & Co. had a return on equity of 9.72% and a net margin of 5.26%.The firm had revenue of $6.29 billion for the quarter, compared to analyst estimates of $6.38 billion. Sell-side analysts predict that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Further Reading